Nathan Tinker Executive Director New York Biotechnology Association New York BizBio 2009 Fighting for a Healthy Biotech Industry

NYBA the voice of New York’s bioscience industry 250 member companies Advocacy –Public Policy –Annual Bio Advocacy Day –Relationships with State and Federal delegations Networking –Annual Meeting (April 20-21, NYC) –NewX2 Biocruise (June 19) –Regional events –LinkedIn community Information –State of the Industry Report –Website –Member news –Industry and competitive intelligence

Why is bioscience important to New York? Research Discovery Technology Transfer & Business Development New Medical Devices, Tests, Drugs & Related Services Better Health Care, Health & Quality of Life New Jobs

New York bioscience is... state-wide

New York bioscience is... business 746 establishments biotechnology medical devices medicinal botanical manufacturing pharmaceutical preparation manufacturing in-vitro diagnostic substance manufacturing biological product manufacturing life sciences research

New York bioscience is... economic impact $16 billion in direct economic output $29 billion in total economic output

New York bioscience is... wages $3.8 billion in direct wages Total biomedical wages in New York rose 16.9% % Change Drug & Chemical Mfg13.8% Labs & Research17.1% Med Equip & Supplies22.3%

New York bioscience is... tax revenue $121 million in direct State taxes

New York bioscience is... clinical trials 5,053 clinical trial sites (2nd in the nation)

New York bioscience is... jobs 55,446 direct 75,018 indirect/induced 130,464

New York bioscience is... jobs 55,446 direct

New York bioscience is % of all biopharmaceutical output nationally

but...

There is no state strategy for biopharma economic development and no structure to develop one.

Critical requirements Discovery, Innovation and Technology Development State funding to fill gap in shrinking federal support of scientific innovation and new technology development Financing, Investment and Business Development Funding and business resources to support early-stage corporate development in the capital-intensive life sciences industry Facilities, Incubation and Expansion Appropriate facilities (lab space, prototyping, & manufacturing) and infrastructure to support nascent and expanding companies Workforce, Training and Entrepreneurship Institutional- and community-based initiatives to continue expanding skilled, multi- disciplinary workforce to support industry growth Taxes, Incentives and Quality of Life Pro-business programs and incentives – and program application assistance- to improve economic conditions for new and expanding companies and their employees Marketing, Outreach and Strategic Networking Statewide, asset- and opportunity-driven attraction and retention plan

Massachusetts’s loss, New York’s gain? Boston Globe, Jan 22 & 28 Recent Massachusetts legislation, aimed at promoting cost containment and transparency in health care, included a provision that would forbid any kind of payments from biopharma companies or medical device manufacturing companies to a doctor in the State of Massachusetts, including clinical trials and other vital research. Result: MA companies have begun looking elsewhere. Major conventions have cancelled contracts.

How can Albany help? Maintain a supportive regulatory environment Protect patient access to drugs, devices and therapeutics Expand the QETC Provide full funding the Empire State Stem Cell Initiative

Facts to remember 55,000+ direct jobs 75,000+ indirect/induced jobs $16 billion in direct economic impact $121 million in state taxes $3.8 billion in direct wages 6.8% of all direct biopharmaceutical output nationally

Nathan Tinker NYBA (631)